Soleus Private Equity Fund III L.P. 13D and 13G filings for Inhibikase Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-10-28 4:00 pm Purchase | 2024-10-21 | 13G | Inhibikase Therapeutics, Inc. IKT | Soleus Private Equity Fund III L.P. | 7,228,908 9.990% | 7,228,908 (New Position) | Filing |